News

Asieris to publish the study protocol of Cevira® as a novel treatment in patients with high grade squamous intraepithelial lesion (HSIL) on BMJ Open

2022 ASCO, Asieris Presented a Study Protocol of Muscle Invasive Bladder Cancer(MIBC)

Asieris to present a study protocol of APL-1202 in combination with BeiGene’s tislelizumab as neoadjuvant therapy (NAC) for muscle invasive bladder cancer (MIBC) patients at 2022 ASCO annual meeting

Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy

Now Hiring: Lab Manager (San Francisco)

Now Hiring: Operations Manager (San Francisco)

Now Hiring: Head of Toxicology, Director to Senior Director (Shanghai or San Francisco)

Hexvix® Has Obtained CDE Approval to Carry Out Clinical Real-World Evidence Study

Now Hiring: (Associate) Project Director, Project Management

Now Hiring: Clinical Pharmacologist